We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+20.92%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.42B
AUM Growth
+$350M
Cap. Flow
+$135M
Cap. Flow %
5.56%
Top 10 Hldgs %
42.31%
Holding
83
New
4
Increased
11
Reduced
18
Closed
3

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$67.3M
2
THRD
Third Harmonic Bio
THRD
+$63.1M
3
RVMD icon
Revolution Medicines
RVMD
+$22M
4
ALLK
Allakos
ALLK
+$21M
5
VERV
Verve Therapeutics
VERV
+$20.7M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$32.9M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$25.1M
3
EQRX
EQRx, Inc. Common Stock
EQRX
+$23.4M
4
MRUS
Merus
MRUS
+$15.2M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
26
DELISTED
Nuvalent
NUVL
$32.4M 1.34%
1,666,282
– –
FDMT icon
27
4D Molecular Therapeutics
FDMT
$538M
$32.2M 1.33%
4,007,413
– –
COGT icon
28
Cogent Biosciences
COGT
$6.82B
$31.1M 1.28%
2,084,824
-172,350
-8% -$2.36M
ALLK
29
DELISTED
Allakos
ALLK
$30.6M 1.27%
+5,006,921
New +$21M
EQRX
30
DELISTED
EQRx, Inc. Common Stock
EQRX
$29.7M 1.23%
6,008,187
-4,640,340
-44% -$23.4M
ANTX icon
31
AN2 Therapeutics
ANTX
$198M
$28.1M 1.16%
1,616,665
– –
CNTA
32
DELISTED
Centessa Pharmaceuticals
CNTA
$27.7M 1.14%
6,894,345
– –
CNCE
33
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$24.3M 1%
3,629,000
– –
ACIU icon
34
AC Immune
ACIU
$226M
$23.5M 0.97%
7,428,379
– –
ANNX icon
35
Annexon
ANNX
$839M
$23.4M 0.97%
3,780,694
– –
VERV
36
DELISTED
Verve Therapeutics
VERV
$22.3M 0.92%
+650,000
New +$20.7M
TYRA icon
37
Tyra Biosciences
TYRA
$1.91B
$21.7M 0.9%
2,472,327
– –
OLMA icon
38
Olema Pharmaceuticals
OLMA
$1.02B
$21M 0.87%
7,611,503
– –
JANX icon
39
Janux Therapeutics
JANX
$932M
$19.9M 0.82%
1,470,334
– –
STRO icon
40
Sutro Biopharma
STRO
$408M
$19.1M 0.79%
344,795
– –
ETNB
41
DELISTED
89bio
ETNB
$18.2M 0.75%
3,143,682
-754,318
-19% -$3.31M
RAIN
42
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$17.2M 0.71%
3,526,729
– –
VSTM icon
43
Verastem
VSTM
$502M
$17M 0.7%
1,664,555
– –
VIGL
44
DELISTED
Vigil Neuroscience
VIGL
$16.5M 0.68%
+1,813,633
New +$13.3M
REPL icon
45
Replimune Group
REPL
$904M
$16M 0.66%
926,529
– –
EPIX
46
DELISTED
ESSA Pharma
EPIX
$15.9M 0.66%
8,748,629
+5,050,000
+137% +$13.3M
VIRX
47
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$15.4M 0.64%
3,614,662
– –
SLN
48
Silence Therapeutics
SLN
$526M
$14.9M 0.62%
1,508,416
+841,750
+126% +$8.86M
OVID icon
49
Ovid Therapeutics
OVID
$424M
$12.6M 0.52%
6,851,051
– –
WHWK
50
Whitehawk Therapeutics
WHWK
$191M
$12.4M 0.51%
879,085
– –
1
2
3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2022 Portfolio in Review

As of Q3 2022, BVF Inc held 83 positions worth $2.42B, up 17% from $2.07B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

BVF Inc deployed $135M of net new capital in Q3 2022, opening 4 new positions and adding to 11 existing holdings. Its largest new stake was Third Harmonic Bio: 3,501,814 shares worth $66.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $32.9M trimmed.

  • BVF Inc's largest Q3 2022 buy was Third Harmonic Bio: 3,501,814 shares worth $66.4M.
  • BVF Inc added most to Ionis Pharmaceuticals in Q3 2022, an estimated $67.3M increase.
  • BVF Inc's biggest Q3 2022 reduction was Arcus Biosciences, cutting an estimated $32.9M.
  • BVF Inc fully exited Protagonist Therapeutics in Q3 2022, selling an estimated $8.76M.
  • BVF Inc's ten largest holdings make up 42% of its $2.42B portfolio in Q3 2022.
  • BVF Inc opened 4 new positions and closed 3 in Q3 2022.
  • BVF Inc's portfolio value rose 17% quarter-over-quarter to $2.42B.

Based on BVF Inc's 13F filing for Q3 2022, filed 14 Nov 2022.